409 related articles for article (PubMed ID: 28193854)
1. Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy.
Woo CJ; Maier VK; Davey R; Brennan J; Li G; Brothers J; Schwartz B; Gordo S; Kasper A; Okamoto TR; Johansson HE; Mandefro B; Sareen D; Bialek P; Chau BN; Bhat B; Bullough D; Barsoum J
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1509-E1518. PubMed ID: 28193854
[TBL] [Abstract][Full Text] [Related]
2. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
[TBL] [Abstract][Full Text] [Related]
3. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
Wood MJA; Talbot K; Bowerman M
Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
[TBL] [Abstract][Full Text] [Related]
4. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.
Kannan A; Jiang X; He L; Ahmad S; Gangwani L
Brain; 2020 Jan; 143(1):69-93. PubMed ID: 31828288
[TBL] [Abstract][Full Text] [Related]
5. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
Chen TH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
[TBL] [Abstract][Full Text] [Related]
6. Genomic Variability in the Survival Motor Neuron Genes (
Butchbach MER
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360669
[TBL] [Abstract][Full Text] [Related]
7. Therapeutics development for spinal muscular atrophy.
Sumner CJ
NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
Singh NN; Lee BM; DiDonato CJ; Singh RN
Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
[TBL] [Abstract][Full Text] [Related]
9. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
10. Disease mechanisms and therapeutic approaches in spinal muscular atrophy.
Tisdale S; Pellizzoni L
J Neurosci; 2015 Jun; 35(23):8691-700. PubMed ID: 26063904
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
[TBL] [Abstract][Full Text] [Related]
12. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs.
Madocsai C; Lim SR; Geib T; Lam BJ; Hertel KJ
Mol Ther; 2005 Dec; 12(6):1013-22. PubMed ID: 16226920
[TBL] [Abstract][Full Text] [Related]
13. Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy.
Groen EJN; Perenthaler E; Courtney NL; Jordan CY; Shorrock HK; van der Hoorn D; Huang YT; Murray LM; Viero G; Gillingwater TH
Hum Mol Genet; 2018 Aug; 27(16):2851-2862. PubMed ID: 29790918
[TBL] [Abstract][Full Text] [Related]
14. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
[TBL] [Abstract][Full Text] [Related]
15. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
Shababi M; Glascock J; Lorson CL
Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
[TBL] [Abstract][Full Text] [Related]
16. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA.
Zhang ML; Lorson CL; Androphy EJ; Zhou J
Gene Ther; 2001 Oct; 8(20):1532-8. PubMed ID: 11704813
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells.
Grzeschik SM; Ganta M; Prior TW; Heavlin WD; Wang CH
Ann Neurol; 2005 Aug; 58(2):194-202. PubMed ID: 16049920
[TBL] [Abstract][Full Text] [Related]
18. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7.
Cho S; Moon H; Loh TJ; Oh HK; Cho S; Choy HE; Song WK; Chun JS; Zheng X; Shen H
Biochim Biophys Acta; 2014; 1839(4):306-15. PubMed ID: 24533984
[TBL] [Abstract][Full Text] [Related]
19. Normalization of Patient-Identified Plasma Biomarkers in SMNĪ7 Mice following Postnatal SMN Restoration.
Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
[TBL] [Abstract][Full Text] [Related]
20. Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy.
Sun Y; Grimmler M; Schwarzer V; Schoenen F; Fischer U; Wirth B
Hum Mutat; 2005 Jan; 25(1):64-71. PubMed ID: 15580564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
